º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Pharmaceutical firm ChargePoint reports year of international success and impressive sales growth

Clients range from world’s top pharmaceutical companies to smaller, independent firms

The Liverpool headquarters of pharmaceutical firm ChargePoint

A Merseyside pharmaceutical manufacturer has reported strong sales growth after a year of new product launches and "international success".

The firm, based in Liverpool, reported 5% growth in sales to £12.9m (2017: £12.3m) for the year for December 2018, driven by strong trading results in its º£½ÇÊÓÆµ, European and Indian markets. That's as well as achieving several new contract wins in Canada, strengthening its presence further in North America.

ChargePoint Technology, whose º£½ÇÊÓÆµ headquarters are at Venture Point Business Park in Speke, manufactures high-performance containment and sterile transfer valves and bags.

Its patented technology is used by clients ranging from the world’s top pharmaceutical companies through to smaller, independent manufacturers.

Chris Eccles, CEO of the firm, said: “This has been a great year for ChargePoint, building on the success of our AseptiSafe biovalve launch in 2017 and accelerating growth even further through the launch of Verifi and other new products.

"We have bolstered our reputation as one of the top global providers of contained transfer valves, working with leading pharma companies and manufacturers to deliver the most innovative and high-quality products to our clients.

“The continued support we received from LDC has been instrumental in allowing us to maintain growth, champion R&D and realise our global expansion ambitions. We have a number of exciting product developments in the pipeline, and look forward to evolving our offering even further throughout 2019.”